RecruitingPhase 4NCT05362292

TReating Incontinence for Underlying Mental and Physical Health

Cognitive, Urinary, and Functional Trajectories of Older Women Using Pharmacologic Treatment Strategies for Urgency Incontinence


Sponsor

University of California, San Francisco

Enrollment

270 participants

Start Date

Oct 4, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The TRIUMPH study is a randomized, double-blinded, 3-arm, parallel-group trial designed to compare the effects of anticholinergic bladder therapy versus a) beta-3-adrenergic agonist bladder therapy and b) no bladder pharmacotherapy on cognitive, urinary, and other aging-related functional outcomes in ambulatory older women with urgency-predominant urinary incontinence and either normal or mildly impaired cognitive function at baseline.


Eligibility

Sex: FEMALEMin Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Mirabegron, a drug called Placebo, and others for people with incontinence, incontinence, urge, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include women aged 60 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTolterodine Tartrate ER

Anticholinergic

DRUGMirabegron

Beta-3-adrenergic agonist

DRUGPlacebo

matching placebo pill


Locations(2)

Stanford University

Palo Alto, California, United States

University of California San Francisco

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05362292


Related Trials